Rocket Pharmaceuticals (NASDAQ:RCKT) CEO Gaurav Shah Sells 55,684 Shares

Posted by Brian Himes on May 26th, 2026

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) CEO Gaurav Shah sold 55,684 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $3.09, for a total value of $172,063.56. Following the transaction, the chief executive officer directly owned 1,061,724 shares of the company’s stock, valued at approximately $3,280,727.16. This trade represents a 4.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Gaurav Shah also recently made the following trade(s):

On Tuesday, May 19th, Gaurav Shah sold 2,409 shares of Rocket Pharmaceuticals stock. The stock was sold at an average price of $3.01, for a total value of $7,251.09.
On Wednesday, May 13th, Gaurav Shah sold 2,728 shares of Rocket Pharmaceuticals stock. The stock was sold at an average price of $3.61, for a total value of $9,848.08.

Rocket Pharmaceuticals Stock Up 1.4%

Shares of Rocket Pharmaceuticals stock traded up $0.04 on Tuesday, reaching $3.00. 1,980,141 shares of the company were exchanged, compared to its average volume of 2,201,764. Rocket Pharmaceuticals, Inc. has a one year low of $2.19 and a one year high of $5.45. The company has a market capitalization of $327.57 million, a price-to-earnings ratio of -1.60 and a beta of 0.52. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.08. The company has a 50-day moving average of $3.68 and a 200 day moving average of $3.64.

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). During the same period in the prior year, the company posted ($0.56) earnings per share. On average, equities research analysts forecast that Rocket Pharmaceuticals, Inc. will post -1.24 earnings per share for the current year.

Institutional Investors Weigh In On Rocket Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in RCKT. Monaco Asset Management SAM raised its stake in Rocket Pharmaceuticals by 538.8% in the 3rd quarter. Monaco Asset Management SAM now owns 2,892,261 shares of the biotechnology company’s stock valued at $9,429,000 after acquiring an additional 2,439,494 shares during the period. MPM Bioimpact LLC raised its stake in Rocket Pharmaceuticals by 141.2% in the 2nd quarter. MPM Bioimpact LLC now owns 3,903,081 shares of the biotechnology company’s stock valued at $9,563,000 after acquiring an additional 2,284,816 shares during the period. Qube Research & Technologies Ltd raised its stake in Rocket Pharmaceuticals by 690.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 1,548,262 shares of the biotechnology company’s stock valued at $3,793,000 after acquiring an additional 1,352,469 shares during the period. Millennium Management LLC raised its stake in Rocket Pharmaceuticals by 52.0% in the 3rd quarter. Millennium Management LLC now owns 3,570,391 shares of the biotechnology company’s stock valued at $11,639,000 after acquiring an additional 1,221,554 shares during the period. Finally, Maverick Capital Ltd. raised its stake in Rocket Pharmaceuticals by 42.0% in the 1st quarter. Maverick Capital Ltd. now owns 3,567,372 shares of the biotechnology company’s stock valued at $12,771,000 after acquiring an additional 1,054,262 shares during the period. Institutional investors own 98.39% of the company’s stock.

Analyst Upgrades and Downgrades

RCKT has been the topic of a number of analyst reports. Cantor Fitzgerald upped their price objective on Rocket Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Friday, February 27th. Lifesci Capital upgraded Rocket Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, February 26th. The Goldman Sachs Group upped their price objective on Rocket Pharmaceuticals to $3.00 and gave the stock a “sell” rating in a research note on Monday, March 2nd. Bank of America upped their price objective on Rocket Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Monday, March 30th. Finally, Weiss Ratings cut Rocket Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $11.54.

View Our Latest Analysis on Rocket Pharmaceuticals

Rocket Pharmaceuticals Company Profile

(Get Free Report)

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.